The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

about

Prevalence of Arthritis in Africa: A Systematic Review and Meta-Analysis MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis.Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy.

P2860

Q26799121-C7C639BC-C1CF-456F-A3A9-6404DBDE49A8 Q38628638-1AB928D3-BB59-485D-B3E9-525EA6DB2C83 Q49387423-BBFA2F94-86D7-4401-A66D-7E1DE4EC7F51

P2860

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q38314640

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

@en

type

Item

label

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

@en

prefLabel

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

@en

P1476

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

@en

P2093

Paweł Kawalec

http://www.w3.org/2001/XMLSchema#string

P2860

The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.

Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.

Ankylosing spondylitis: what is the cost to society, and can it be reduced?

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Costs of ankylosing spondylitis in three European countries: the patient's perspective.

Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

Costs and quality of life of patients with ankylosing spondylitis in Hong Kong.

P304

285-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1586/14737167.2015.1001370

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krzysztof Piotr Malinowski

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25579502

http://www.w3.org/2001/XMLSchema#string

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

about

P2860

P2860

The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698